Cancel
Michael Hotchkin
Chief Development Officer
@
Clene Nanomedicine
5s9g22f@37380.1y4
Sign up to see email
Known information
- Has more than 20 years of experience in pharmaceutical commercialization, planning, strategy development, and medical affairs.
- Was a founding team member at Actelion Pharmaceuticals US, Inc.
- Helped launch multiple best-in-class products for orphan disorders at Actelion Pharmaceuticals.
- Led the commercialization efforts for Actelion’s Genetic Business Unit, including clinical development activities which resulted in the doubling of sales for two different pharmaceutical drugs.
- Implemented new market planning activities for Actelion globally.
- Directed U.S. strategy development and led marketing activities for multiple medicines at Actelion.
- Began career at Parke-Davis, a subsidiary of Pfizer.
About Clene Nanomedicine
Clene Nanomedicine is a biopharmaceutical company focused on developing nanotherapeutics for neurodegenerative diseases, with its lead candidate, CNM-Au8, targeting ALS, MS, and Parkinson's Disease.
Report inaccurate information
